Why Crescent Biopharma, Inc.’s (CBIO) Stock Is Down 5.26%
As of Friday, July 31, Crescent Biopharma, Inc.’s CBIO share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Crescent Biopharma, Inc.’s (CBIO) Stock Is Down 6.14%
As of Wednesday, July 29, Crescent Biopharma, Inc.’s CBIO share price has dipped by 6.14%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Crescent Biopharma, Inc.’s (CBIO) Stock Is Up 7.12%
As of Monday, July 27, Crescent Biopharma, Inc.’s CBIO share price has surged by 7.12%, which has investors questioning if this is right time to sell.Michael Rose
Why Crescent Biopharma, Inc.’s (CBIO) Stock Is Up 5.50%
As of Thursday, July 23, Crescent Biopharma, Inc.’s CBIO share price has surged by 5.50%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Crescent Biopharma, Inc.’s (CBIO) Stock Is Down 5.77%
As of Wednesday, July 22, Crescent Biopharma, Inc.’s CBIO share price has dipped by 5.77%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | CBIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $620.7 | $251.9 | 40% |
|
| Shares Out (Mil) | 33.3 | 50.8 | 39% |
|
| Institutional Ownership | 90.1% | 92.0% | 58% |
|
| Float (Mil) | 20.1 | 40.5 | 29% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 361 | 447 | 54% |
|
| Price Change (52-week) |
22.1% | 54.2% | 64% |
|
| Growth | CBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | na | (9.8%) | na |
|
| EPS (5yr) | na | 16.3% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.640) | ($2.493) | ($2.977) | |
| Month Ago EPS | ($0.640) | ($2.620) | ($2.943) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.640) | ($2.620) | ($2.943) | |
| Year/Year Chg | (8.4%) | (80.5%) | (73.1%) | |
| Financials | CBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $12 | $39 | 10% |
|
| Net Income (TTM) (Mil) | ($162) | ($43) | 8% |
|
| EPS (TTM) | ($8.047) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($70) | ($30) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $167 | $3 | 83% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $5 | 18% |
|
| Enterprise Value (Q1) (Mil) | $433 | $182 | 33% |
|
| Valuation | CBIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.78 | 2.60 | 62% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CBIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 63.8% | 96% |
|
| Net Margin | na | (64.7%) | na |
|
| ROA | (144.2%) | (49.7%) | 3% |
|
| ROE | (216.6%) | (55.4%) | 4% |
|
| Liabilities to Assets | 7.7% | 30.3% | 4% |
|
| F-Score | 2 | 3 | na |
|
Crescent Biopharma, Inc. did not pass any screens on 7/30/2026.
